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Cost Evaluation of Evidence-Based Treatments
M
any treatment programs have adopted or are considering adopting evidence-based treatments (EBTs). When a pro-
gram evaluates whether to adopt a new intervention, it must consider program objectives, operational goals, and 
costs. This article examines cost concepts, cost estimation, and use of cost information to make the final decision on whether to 
adopt an EBT. Cost categories, including variable and fixed, accounting and opportunity, and costs borne by patients and others, 
are defined and illustrated using the example of expenditures for contingency management. Ultimately, cost is one consideration 
in the overall determination of whether implementing an EBT is the best use of a program’s resources.
S 
ubstance abuse treatment programs continually pursue the operational 
goals of providing effective treatments to clients and maintaining a stable 
business. Many programs have adopted or are considering evidence-based 
treatments (EBTs) as a way to advance both objectives. These are interventions 
that have demonstrated their ability to enhance patient retention, abstinence, 
and/or other desirable outcomes when compared with clinics’ established treat-
ments. Programs that adopt EBTs may improve revenue flows by attracting new 
clients and by drawing referrals and funding from sources that require the use of 
interventions with proven efficacy.
This article aims to help programs considering whether to adopt an EBT. We 
briefly discuss criteria for identifying suitable EBTs and then focus primarily on 
costs: basic cost concepts, cost estimation, and the use of cost information in the 
final adoption decision. Ultimately, a program’s assessment of its organizational 
goals and traits, together with an analysis of costs, prepares it to determine whether 
implementing an EBT will produce adequate value. We illustrate concepts using 
the example of contingency management (CM), an EBT that has been shown to 
enhance outcomes in a variety of treatment settings.
 
firSt StepS: DefininG GoalS, iDentifyinG conStraintS 
Programs have many EBTs to choose from, both psychotherapeutic (e.g., 
motivational interviewing [MI], cognitive-behavioral therapies [CBTs], 
CM, and family-based models such as multisystemic therapy) and pharma-
cological (e.g., buprenorphine/naloxone, naltrexone, disulfiram, acampro-
sate, and medications for co-occurring medical or psychiatric disorders). For a 
comprehensive list, see www.nrepp.samhsa.gov.Not all EBTs are equally suitable for every program. 
Before focusing on any specific EBT, a program should 
clarify what it hopes to accomplish by implementing a 
new intervention. One primary goal will almost always 
be to provide more effective treatment; another is likely 
to be to ensure financial stability or make a profit; and a 
third might be to attract more clients from new demo-
graphic groups, users of other types of drugs, or individu-
als referred from new sources (e.g., criminal justice, child 
protection, or employee assistance systems). Programs 
may implement EBTs to attract, develop, and retain staff 
members who are highly skilled, knowledgeable about 
advances in the field, and engaged in quality improve-
ment. A program may see EBT adoption as an effective 
strategy to improve its ability to compete successfully 
with other programs and maintain a reputation as an 
innovative and effective provider of addiction treatment. 
Clinics that receive public funding, and hence have a 
responsibility to society at large, may utilize EBTs to 
improve secondary outcomes of drug abuse treatment 
such as reducing the spread of disease (tuberculosis, 
HIV/AIDS), crime, and unemployment.
Whatever the reasons for a program’s interest in 
EBTs, its client, organizational, and funder characteristics 
delimit the set of potentially suitable interventions (see 
Table 1). In general, a clinic will want to consider only 
EBTs that have demonstrated efficacy, in several studies, 
among patients who are similar to those it intends to 
treat—for example, in terms of primary drugs of abuse, 
age (e.g., adolescent or adult), gender, co-occurring 
disorders, and other problems (Harwood and Myers, 
2004). Before moving ahead with an EBT, a program 
should be confident that clinic staff either possess the 
skills to administer the intervention effectively or can 
be trained to do so. Otherwise, inadequate skill levels 
or negative attitudes may hinder or preclude effective 
delivery, no matter how well the intervention performed 
in controlled clinical trials. For example, a program 
whose staff objects to paying patients for abstinence may 
not attain the same outcomes from CM as one whose 
staff accepts the intervention’s underlying rationale 
of tangible positive reinforcement for achieving treat-
ment goals. Similarly, with regard to funders, a model 
that provides incentives, or one that emphasizes harm 
reduction and client choice rather than abstinence and 
treatment compliance, might not obtain buy-in from 
the criminal justice or child protection systems.
Once a program has defined its goals and constraints, 
it can match them to available EBTs by consulting a 
growing reservoir of published materials. These include 
EBT psychotherapy manuals, pharmacotherapy proto-
cols, computer programs, and other guidelines that have 
been made available by the National Institute on Drug 
Abuse (NIDA), the Center for Substance Abuse Treat-
ment (CSAT), the Substance Abuse and Mental Health 
Services Administration (SAMHSA), and other sources 
(see Resources for EBT Decisionmaking on page 48). 
coSt anD valUe 
Before committing to an EBT, a program should answer 
three key questions regarding costs: 
• What evidence-based treatments (EBTs) are available? Which would be 
most suitable, be most likely to be effective, and give the greatest value to 
the clinic?
• How strong and generalizable are the effectiveness findings? Do the find-
ings apply to the clinic characteristics and clinic’s clients (e.g., primary 
drug use, women, adolescents, criminal justice clients)?
• Does the treatment improve the outcomes that the clinic, client, and staff 
care most about (e.g., abstinence, reduced drug use, reduced crime, bet-
ter family functioning, increased employment, harm reduction)?
• Is the EBT a good match to the clinic in terms of staff, clients, payers, etc.?
• Will adopting one treatment prevent, or facilitate, the adoption of others 
now or later?
• Will clients and those referring clients (e.g., criminal justice system) be 
interested in and satisfied with this treatment?
• What, if any, will be the extra costs of adoption, staff training, new staff, 
management time, etc.?
• Will payers be willing to pay for any extra costs? Which payers and how 
much?
• Will staff be eager to adopt? Will adopting the EBT affect staff morale? Will 
it affect satisfaction and turnover? Is there a staff champion of the EBT?
• How difficult and expensive will it be to provide high-quality, effective care 
(e.g., fidelity to psychotherapies)?
• How available, user-friendly, and costly are the methods available to learn 
and adopt the new EBT and/or obtain technical assistance?
• Should the EBT be phased in slowly or fully adopted immediately?
• Can the adoption decision be reversed without large costs to the clinic if it 
proves to be a poor decision?
• Should all the patients get this treatment?
• What are the benefits to adopting? The costs? Do the incremental costs 
outweigh the benefits gained?
• To what extent does the clinic want to follow up and evaluate costs and 
profits as well as staff satisfaction?
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• What will be the fixed and variable costs of implement-
ing and maintaining the EBT? 
• Will the intervention increase, decrease, or have no 
impact upon the financial bottom line? 
• Will the intervention be the best use of the resources 
that it will require?
The first and second questions are strictly financial: 
their answers indicate whether the program will have 
sufficient resources to implement and maintain the new 
intervention and the potential impact on profitability. 
The third question is about value. To answer it, the 
program must weigh all the advantages expected from 
the EBT—e.g., monetary benefits, improved client 
outcomes, public health improvements—against what 
might be obtained by dedicating the same amount of 
resources to the next best available use (see Table 2). 
Whatever the outcome of the cost inquiries, adoption 
of the EBT is only suitable if the answer to the value 
question is affirmative. 
coSt cateGorieS
EBTs vary widely in what they require in terms of train-
ing, equipment, counselor time, and other inputs and in 
the cost of the inputs. For example, pharmacotherapies 
involve outlays for medication, associated tests, physi-
cian and nursing time, storage, and inventory control; 
psychosocial treatments entail expenditures for initial 
training as well as ongoing supervision and retraining. 
Costs may also vary with the scale of operation, the type 
of clinic, and even the geographic location. The impact 
of each specific cost on the desirability of implementing 
an EBT depends upon whether it is (1) variable or fixed, 
(2) accounting or opportunity, (3) paid by the clinic, 
patients, and payers, or society at large.
variable and fixed costs
Most EBT costs are variable. This category includes 
any expenditure that is tied directly to the number of 
patients or service units provided. Counselor time and 
medications are core variable costs. Depending on the 
specific procedures used, a program’s outlays for training 
activities and clinical supervision to maintain fidelity to 
an EBT may also count as variable costs. 
A program can tally variable costs to predict the 
cost consequences of a new policy, such as increasing its 
census or implementing an EBT. For example, suppose a 
program contemplates expanding the number of patient 
slots for buprenorphine maintenance therapy. As long 
as the cost of buprenorphine remains unchanged, the 
program can project additional variable costs based on 
the number of new patients and the average cost of the 
medication per current patient. However, suppose a 
program adopts an EBT that requires patients to attend 
more frequent counseling sessions than the program’s 
prior standard. In this case, the program’s new outlays 
for counseling time will reflect both the number of new 
patients and a higher per-patient outlay for counseling 
time.
The fixed costs of a treatment include overhead such 
as rent, mortgage, insurance, and other contracts and 
expenses that remain stable over a long period of time, 
typically a year or more. As an illustration, a program 
that to date has provided only psychosocial services but 
now plans to implement a pharmaceutical EBT will 
anticipate new variable costs (cost of the medication), 
and also new fixed costs to maintain a pharmacy—e.g., 
rent (if a new space is needed), upkeep, and costs related 
to stocking the medication and fulfilling regulatory 
requirements. As another example, a program that adds 
prize-based CM to its service offerings will project new 
variable expenditures for prizes and new fixed costs to 
acquire and store prizes and manage the prize system. 
A program may consider a new EBT a financial suc-
cess if it produces sufficient income simply to allay its 
own variable or total costs, or the program may require 
that the intervention help allay preexisting overhead as 
well. As with variable costs, there is an interplay between 
the fixed and per-patient costs of an EBT. For example, 
if the rental cost for pharmacy space is the same whether 
20 or 100 patients receive medications, the per-patient 
cost will be smaller if 100 patients are served. Because 
of this interplay, an EBT may be fiscally unfeasible at a 
small scale yet profitable at a larger scale. 
accounting and opportunity costs 
Variable and fixed EBT-related outlays are often also 
opportunity costs, defined as disbursements that might 
alternatively be used for other ends. For example, an 
EBT-related outlay that is paid from a program’s oper-
ating surplus  represents an opportunity cost, since the 
program has the option to use that money to pursue its 
aims in any way it chooses—such as to expand its pres-
ent services or lower patient fees. In contrast, an EBT-
related outlay that is paid entirely from a grant that is 
made specifically to support that particular intervention 
is not an opportunity cost, because the program must 
either use that money for the EBT or return it to the 
granting agency. The opportunity cost of adopting one 
the opportu-
nity cost of 
adoption of 
one eBt may 
be that another 
one cannot be 
adopted.the impor-
tance of 
cm rewards 
declines 
as patients 
become 
motivated by 
improvements 
in their quality 
of life. 
EBT may be that another one cannot be adopted. The 
concept of opportunity costs reflects the reality that most 
clinics have limited monetary and other resources, and 
implementing a new EBT usually means forgoing other 
opportunities. Opportunity costs indicate the real value 
of resources and should be used in cost and cost-benefit 
considerations.
costs to patients and others
Programs, especially public programs, must also consider 
EBT-related costs that will be borne by their patients, 
patients’ families, and communities. For patients, these 
costs typically can include fuel or fares for transporta-
tion to clinic visits, costs for child care, and time that is 
spent in the clinic but might otherwise be used to earn 
wages or for other positive activities. A patient’s family 
may have parallel expenditures if members accompany 
the patient to the clinic, participate in family therapy, 
or provide other support, such as child care.
An EBT that imposes unacceptably high costs upon 
patients or other stakeholders may attract fewer clients or 
experience lower adherence to treatment. For example, an 
intervention that requires fewer clinic visits may appeal 
to patients more than one that requires more clinic visits, 
even though the latter might yield superior benefits for 
those who stick with it.
additional costs
Along with the costs to deliver a particular EBT, clinics 
may incur indirect costs as a result of changes related inci-
dentally to implementing the intervention. For example, 
if patients increase adherence and attend the clinic longer 
with the new EBT, they will generate more treatment 
costs. In such a case, the additional treatment costs might 
or might not be offset by the increased revenue from the 
patients’ additional clinic sessions.
pUttinG nUmBerS to conceptS:  coStinG 
oUt cm
CM is a robust psychosocial EBT that has improved 
outcomes in clinical trials with abusers of a wide range 
of substances in a variety of treatment settings. At the 
core of CM is the use of tangible rewards to reinforce 
abstinence, attendance, and/or the achievement of pro-
social or recovery-oriented goals. Patients typically earn 
cash, a prize, or a voucher for goods or services each 
time they present objective evidence of commitment 
or progress in treatment. CM interventions most com-
monly reward drug-free urine or breathalyzer tests, and 
some give prizes for attendance and participation in 
counseling sessions. CM has been shown to improve 
abstinence, length of stay in treatment, clinic atten-
dance, and medication compliance (Lussier et al., 2006).   
   Early CM incentive programs were relatively expensive, 
but more recent CM designs have reduced costs while 
maintaining effectiveness. The three most significant 
CM outlays, discussed below, are the reward payments 
to patients, drug test kits, and labor to administer the 
incentive intervention. Each rises and falls in close cor-
relation with the number of patients and so is a variable 
cost. Fixed costs of CM include establishing a reward and 
tracking system. An indirect effect may be that patients 
in CM stay longer; this could result in greater costs as 
well as greater reimbursement.
reward payments
The cost of reward payments in CM depends on the 
structure and generosity of the prize schedule, the cli-
entele and their successes, the frequency of testing, and 
the effectiveness of the underlying usual care. The first 
tested version of CM gave cash rewards that totaled as 
much as $1,000 to each patient who remained abstinent 
throughout a 12-week treatment period (Higgins et al., 
2000). Subsequent CM models have reduced costs by 
using a lottery system to award prizes (so that only a por-
tion of patients meeting reward criteria receive rewards 
with monetary value), de-escalating payments in the later 
stages of treatment, and/or using nonmonetary rewards 
such as the right to take home medications. Petry and 
colleagues (2004) developed an incentive program in 
which patients who provide drug-free tests earn the right 
to draw for a set of prizes; the number of draws increases 
as the number of days of continuous abstinence increases. 
In a clinical trial, this design improved abstinence with 
total average payouts ranging from $36 to $68 (Petry 
et al., 2004).
test Kits
CM protocols test frequently for drug use to provide 
patients with ample opportunities to earn the rewards 
that enhance motivation for abstinence. The frequency 
of testing in CM is more than that of most standard 
care protocols, and the added tests constitute a sub-
stantial variable cost of the EBT. For example, if a CM 
protocol schedules patients for two additional tests per 
week, and patients attend all their appointments, the 
clinic may incur costs of $8.40 per patient per week 
($4.20 per urinalysis test cup). In a more realistic sce-
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nario, patients may keep only 50 to 75 percent of their 
appointments and the incremental costs for CM test cups 
decline accordingly. The labor cost for administering 
each urine test has been estimated to average less than 
$2.50. To reduce these costs, some clinics have tried 
reducing the number of drug tests later in treatment, on 
the supposition that the importance of the CM rewards 
declines as patients achieve sufficient recovery to become 
motivated by improvements in their quality of life. Note 
that these cost estimates will, of course, vary over time 
and across geographic areas.
labor costs of operating the reward System
The labor cost to operate a CM reward system will 
depend on the simplicity or complexity of the specific 
protocol, the efficiency with which it is implemented 
and run, and the wage rate of the personnel involved. In 
surveys of clinics in 2002, the total labor cost, includ-
ing shopping for prizes, was estimated to be about $11 
per client per week. However, clinics should be able to 
provide CM less expensively than this because: (1) the 
surveyed clinics employed trained counselors (at about 
$20 to $22 per hour, including fringe benefits) rather 
than technicians to administer the intervention, and (2) 
for purposes of the trial, the clinics did not implement 
CM on an efficient scale.
Note that CM labor costs do not include outlays to 
counselors for administering the standard counseling, 
even though CM patients also receive such counseling. 
This is because CM is implemented as a discrete supple-
ment to standard therapy.
tallyinG anD totalinG coStS
The most appropriate method for estimating the com-
plete costs of an EBT is usually to itemize and price all 
service units that are allocated to the intervention. Service 
units are the specific inputs utilized in the intervention, 
such as an hour of counselors’ time, a dose of medication, 
a drug test kit, recordkeeping, and use of facilities and 
equipment. The quantity of each unit will be estimated 
prior to implementation of the EBT, and then tracked 
following implementation.
The advantage of the service unit approach is that 
it isolates the incremental costs of an EBT—that is, 
the extra expenses that the intervention adds to overall 
operating costs. In a demonstration of this approach, 
Anderson and colleagues (1998) asked program per-
sonnel to keep a diary for 1 week and record each time 
they provided any of 94 different service inputs. The 
researchers used the diaries on unit use plus informa-
tion on the unit price for each input—for example, the 
number of counselor hours and the counselor’s hourly 
wage rate, the price of a drug test kit and the number of 
kits used, use of clinic space and fair market real estate 
values—to calculate the total expenditures related to each 
reSoUrceS for eBt DeciSionmaKinG
The Substance Abuse and Mental Health Services Administration 
(SAMHSA) National Registry of Evidence-based Programs and Practices 
(NREPP; www.nrepp.samhsa.gov) provides definitions of EBTs and a rat-
ing and classification system of the scientific evidence for a range of sub-
stance abuse and mental health treatments. Descriptions of intervention 
implementation and fidelity measurement are intended to help determine 
the practicality of adopting specific treatments in practice settings. 
Although intended for use by applicants for grants through SAMHSA’s 
Center for Substance Abuse Treatment (CSAT), the Inventory of Effective 
Substance Abuse Treatment Practices provides a list of publications that 
may be useful for those considering adoption of EBTs. The Web sites 
(csat.samhsa.gov/treatment.aspx and ncadi.samhsa.gov) provide access 
to descriptions of multiple substance-related interventions, including 
implementation, staffing, and fidelity measurement issues.
SAMHSA has supported the development of numerous resources to 
facilitate technology transfer, including the implementation of EBTs. Its 
Addiction Technology Transfer Centers (www.attcnetwork.org) created a 
very useful resource for community programs considering adoption of 
an EBT. The Change Book: A Blueprint for Technology Transfer, 2nd Edi-
tion (2004), and companion workbook are free downloadable guides 
(www.nattc.org/resPubs/changeBook.html) to the steps involved in put-
ting research-based interventions into practice. The Iowa Consortium 
for Substance Abuse Research and Evaluation developed Evidence-Based 
Practices: An Implementation Guide for Community-Based Substance 
Abuse Treatment (2003), which provides EBT definitions, literature 
reviews, adoption and implementation challenges and barriers, assess-
ments of readiness to change, and evaluation guidelines (www.uiowa.
edu/~iowapic/files/EBP%20Guide%20-%20Revised%205-03.pdf). 
The National Implementation Resource Network (NIRN) operated at 
the University of North Carolina, Chapel Hill, provides a wide array of 
resources related to best practices and the integration of science and 
service within several areas of behavioral health. The NIRN Web site 
(www.fpg.unc.edu/~nirn/) provides information on training institutes, 
conferences, other Web sites focused on dissemination, implementa-
tion research, and technical assistance as well as access to relevant 
articles, reports, and newsletters related to the stages and processes of 
implementation. In collaboration with NIDA and CSAT, the Institute for 
Research, Education and Training in Addictions (IRETA; www.ireta.org/
ireta_main/nida_initiative.htm) provides a range of resources related to 
the implementation of best practices. The Web site contains or provides 
links to information on intervention implementation, technical assis-
tance, fidelity measurement, staff training, and other EBT references.treatment episode. Yates (1999) provides a step-by-step 
description of the use of daily time sheets to estimate 
service unit costs. 
A few published studies have estimated the costs of 
particular EBTs. Programs may use these as benchmarks 
in EBT decisionmaking, but with the caveat that proto-
col, organizational, and contextual differences may result 
in significant cost variance from program to program.
Jones and colleagues (2009) examined the costs of 
providing buprenorphine for opioid dependence. The 
study compared the costs of clinic-based methadone 
(MC), office-based methadone (MO), and office-based 
buprenorphine (BO). Treatment costs were calculated 
over 6 months of maintenance for patients who had 
previously been stabilized for at least 1 year. The total 
monthly cost of treatment per patient was estimated to 
be $147 (MC), $220 (MO), and $336 (BO). Much of 
the cost advantage of methadone was due to its lower 
price, which was $93 (MC) or $86 (MO) per month, 
compared with $257 for buprenorphine. The patients’ 
treatment-related costs (e.g., time taken to attend clinic, 
transportation costs, babysitting costs, etc.) were $92 
(MC), $63 (MO), and $38 (BO).
NIDA’s Clinical Trials Network analyzed the effec-
tiveness and cost-effectiveness of prize-based CM in 
a set of large, multisite trials. In one study, patients 
remained in treatment longer and achieved longer periods 
of abstinence after CM was added to the psychosocial 
services offered by eight outpatient programs (Olmstead, 
Sindelar, and Petry, 2007a). The incremental cost for 
CM was estimated to be $448 (range $306 to $582) per 
treatment episode, with an average patient stay of slightly 
more than 8 weeks. Of this amount, $213 was for prize 
payments, $146 for operating the prize system, $50 for 
testing costs, and $39 for extra counseling costs incurred 
due to clients’ longer stays in treatment.  In a second 
study, the incremental cost to add CM to methadone 
maintenance was $225 overall, of which $130 was dis-
pensed as prizes (Sindelar, Olmstead, and Peirce, 2007). 
Comparison of the results of the two studies suggested 
that adding CM to methadone maintenance was more 
cost-effective than adding the EBT to the psychosocial 
taBle 2. common costs and Benefits of introducing new eBts
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perSpective
Clinic
Patients and Their  
Families
Payers and Society
potential coStS
Staff
• Training and retraining
• Ongoing supervision to ensure fidelity
• Time providing treatment
• Administration such as treatment notes
Management
• Startup and ongoing oversight
Medications
Other Resources
• Space, tests, materials, technical  
  assistance, medical services, etc.
Longer length of stay due to satisfaction
Extra time and travel for additional visits, 
additional tests, etc.
Higher outlays for treatment
potential BenefitS
• More effective treatments
• More satisfied clients
• Reputation for cutting-edge, quality care
• Ability to attract new clients, new and more referrals
• Greater revenue
• More satisfied staff, lower turnover, easier to 
  attract staff
• More effective and durable treatment, resulting in 
– Better mental and physical health
– Greater employment and income
– Greater family functioning
– Reduced expenditures for drugs
– Fewer legal problems
• Reduced crime and fear of crime
• Reduced spread of HIV/AIDS, STDs, hepatitis C, and  
  other contagious diseasesreferenceS
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programs. The likely reason was that the patients in the 
psychosocial programs tended to do fairly well without 
the addition of the EBT. 
Zarkin and colleagues used their Substance Abuse 
Services Cost Analysis Program (SASCAP) to estimate 
the costs of providing methadone (Zarkin, Dunlap, and 
Homsi, 2004). In a sample of 70 programs, they esti-
mated the annual per patient cost to be $4,176, includ-
ing initial assessment, group counseling, medication 
purchase and dispensing, and other cost components. 
They indicated that other similar estimates ranged from 
$2,800 to $6,300 (in 2000 dollars) (Zarkin, Dunlap, 
and Homsi, 2004). Roebuck and colleagues (2003), 
using data from a large number of studies fielded over 
10 years, estimated that the mean cost per patient for 
methadone maintenance was $91 per week, or $7,358 
per treatment episode. The Drug Abuse Treatment Cost 
Analysis Program instrument that was used to make this 
estimate is available online (datcap.com).
Perhaps over time NIDA, CSAT, or other profes-
sional groups could develop a set of template cost calcula-
tions, cost-effectiveness studies, or cost-benefit studies 
that would guide clinics in EBT adoption decisions. 
The information would be most useful with adjust-
ment factors to reflect variable clinic characteristics: for 
example, type (e.g., residential, outpatient, methadone 
maintenance), client population (e.g., mixed gender or 
women only, primary drugs of abuse), funding sources, 
and geographic area. Such efforts would simplify EBT 
decisionmaking and by doing so encourage more wide-
spread adoption of EBTs. 
to aDopt or not?
Substance abuse treatment programs should consider 
implementing EBTs, which have demonstrated their abil-
ity to improve client outcomes and potential to support 
other strategic and financial objectives. By consulting 
the literature, most programs will be able to identify 
a selection of EBTs that are well suited to their goals, 
organizational traits and strengths, and client and funder 
needs and expectations. Cost estimation and analysis 
provide critical information toward the question that 
ultimately should determine the course of action: Among 
all the options we have for using our resources, is this 
the one that will do the most to advance the totality of 
our organizational objectives? 
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